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VRC01, a broadly neutralizing monoclonal antibody (bnmAb), can neutralize a diverse array of HIV-1 isolates by mimicking 
CD4 binding to the envelope glycoprotein gp120. We have previously demonstrated the presence of VRC01-resistant strains in 
an HIV-1 infected patient during antiretroviral therapy. Here, we report follow-up studies of two subsequent samples from the 
same patient. With genetic and phenotypic analysis of over 70 full-length molecular clones of the HIV-1 envelope, we show 
that VRC01-resistant HIV-1 continued to exist and change in its proportion of the infecting virus during treatment with a 
highly active antiretroviral therapy. Consistent with our previous observation, the resistant phenotype was associated with a 
single asparagine residue at position 460 (N460), a potential N-linked glycosylation site in the V5 region. The persistence and 
continuing evolution of VRC01-resistant HIV-1 in vivo presents a great challenge to our future preventative and therapeutic 
interventions based on VRC01. 
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The entry of human immunodeficiency virus type 1 (HIV-1) 
into the target cell is dependent on interactions between the 
viral envelope glycoproteins (gp120 and gp41) and cellular 
receptor CD4 and coreceptors CCR5 or CXCR4 [111]. 
gp120 contains the CD4-binding site (CD4bs), which alt-
hough critical for viral entry, is also the viral Achilles’ heel 
for broadly neutralizing monoclonal antibodies (bnmAbs) 
and polyclonal sera from “elite neutralizers,” who display 
exceptionally strong immune control of viral replication 
[1219]. With the recent advent of microculturing and anti-
gen-specific sorting of B cells from “elite neutralizers”, 
researchers have isolated increasing numbers of bnmAbs 
directed against the CD4bs, including VRC01, VRC03, 
3BNC117, 3BNC55, VRC-PG04, and NIH45-46 [1216, 
20,21]. The prototype VRC01, for instance, was isolated 
from a clade-B-infected individual and neutralized 91% of a 
diverse panel of pseudotyped viruses [13]. VRC03, a close 
relative of VRC01, neutralized about 57% of these viruses 
[13]. More recently isolated CD4bs-directed bnmAbs, in 
particular 3BNC117, 3BNC55, VRC-PG04, and NIH45-46, 
have shown similar or even higher potency and breadth than 
the prototype VRC01 [1416]. Most of these VRC01-like 
bnmAbs share similar recognition mechanisms, reflected by 
their convergence on the recognition of the CD4bs on 
gp120 [1719]. Their primary mechanism of neutralization 
must involve blocking the interaction between the virus and 
receptor CD4 as they compete for the same general area on 
HIV-1 gp120, although it is worth noting that there may be 
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differences in their mechanisms of blocking the gp120-CD4 
receptor interaction [1226]. 
However, despite the superior potency and breadth of 
these bnmAbs, each fails to neutralize a small but signifi-
cant proportion of pseudotyped viruses in each panel. For 
instance, VRC01 was unable to neutralize about 10% of the 
viruses tested [13], and many of those resistant strains were 
not derived from “elite neutralizers”, such as the donor from 
which VRC01 was initially isolated. The rise of VRC01- 
resistant viruses in “ordinary” individuals suggests that such 
variants are either naturally occurring or selected under a 
VRC01-like antibody response at some point during disease 
progression. VRC01-resistant strains have also been identi-
fied in the VRC01 donor [27]. Only selective archival pro-
viral Env variants remained sensitive, whereas all contem-
porary plasma-derived variants were resistant, indicating 
their rapid genetic and phenotypic evolution under strong 
antibody-based selection pressure [27]. 
In the course of characterizing diverse HIV-1 strains iso-
lated from infected patients in China, we have identified 
VRC01-resistant strains derived from CRF08-BC-infected 
patients [28]. We have also demonstrated that the V5 region, 
in particular the asparagine residue at position 460 (N460), 
a potential N-linked glycosylation site (PNGS) in the V5 
region, plays a critical role in determining the VRC01-  
resistant phenotype of these strains [29]. In the present 
study, we determined the in vivo prevalence and evolution 
patterns of VRC01-resistant variants in vivo. With genetic 
and phenotypic analysis of over 70 full-length molecular 
clones of the HIV-1 envelope from blood samples taken 
from a single, previously investigated patient, we show that 
VRC01-resistant HIV-1 persisted and evolved in both its 
proportion and sequence during treatment with a highly 
active antiretroviral therapy. Consistent with our previous 
observation, the resistant phenotype was associated with the 
single asparagine residue at position 460 (N460). The per-
sistence and continuous evolution of VRC01-resistant 
HIV-1 in vivo imposes a tremendous challenge for preven-
tative and therapeutic interventions based on VRC01. 
1  Materials and methods 
1.1  Study subject and PCR amplification of full-length 
gp160 envelope genes 
The study subject is an HIV-1 CRF08_BC-infected intra-
venous drug user, as reported previously [28]. This patient 
has received antiretroviral therapy since 2007 and his plas-
ma viral loads were well suppressed (Table 1). His periph-
eral blood CD4+ T cells increased from 88 cells μL1 on 
July 26, 2007 to 558 cells μL1 on July 20, 2009 (Table 1). 
Our initial study was conducted on a sample collected on 
July 16, 2007 (20070716) and the two samples examined 
here were collected on January 21 and July 20, 2009 
(20090121 and 20090720, respectively), approximately 18  
Table 1  Clinical, virological, and immunological characterization of the 
subject 






2007-7-26 AZT+3TC+NVP <50 88 651 
2007-10-25 AZT+3TC+NVP <50 377 651 
2008-7-25 AZT+3TC+NVP <50 572 1826 
2009-1-21 AZT+3TC+NVP <50 376 na 
2009-7-20 AZT+3TC+NVP <50 558 na 
 
 
and 24 months later (Table 1). This study was approved by 
the ethic committees of the appropriate institutions [28]. 
Peripheral blood mononuclear cells (PBMC) were col-
lected and genomic DNA was extracted with the QIAamp 
DNA Blood Mini Kit (Qiagen, Shanghai, China), according 
to the manufacturer’s protocol. Full-length envelope se-
quence was amplified with nested PCR with HIV-1 sub-
type-B′C-specific primers, as previously reported [28]. The 
PCR product was cloned into the pcDNA™3.1 expression 
vector (Invitrogen, Carlsbad, CA, USA) and verified by 
sequencing. The full-length gp160 amino acid sequence was 
analyzed based on a comparison with HIV-1 HXB2. 
1.2  Antibodies and soluble CD4 
IgG-1 VRC01 antibodies were kindly provided by Dr. John 
Mascola (Vaccine Research Center, National Institute of 
Allergy and Infectious Diseases, National Institutes of 
Health, USA). Samples of IgG-1 b12 were obtained from 
the NIH AIDS Research and Reagents Program. IgG-4 
ibalizumab was kindly provided by Dr. David D. Ho (Aaron 
Diamond AIDS Research Center, The Rockefeller Univer-
sity, USA). 
1.3  Pseudotyped virus production 
The HIV-1 env pseudovirus was generated as described 
previously [28]. Briefly, 293T cells were cotransfected with 
the pcDNA™3.1 expression vector containing the target env 
gene and the pNL4-3R-E-luciferase viral backbone plasmid 
in a 1:3 ratio. The cell culture medium was replaced with 
10% Dulbecco’s modified Eagle’s medium containing fetal 
bovine serum after 4–6 h and then incubated for an addi-
tional 40–48 h at 37°C. The pseudotyped viral supernatants 
were collected after 48 h. The viral titers were quantified by 
measuring the luciferase activity in relative light units (RLU; 
Bright-Glo Luciferase Assay System, Promega Biosciences, 
CA, USA). The supernatants were packaged and stored at 
–80°C. 
1.4  Analysis of viral sensitivity to neutralization 
Neutralization assays were performed as described previ-
ously [29]. In brief, 100 TCID50 of pseudotyped virus was 
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incubated with either serially diluted VRC01, b12, or Ibali-
zumab for 1 h at 37°C before it was used to inoculate 
TZM-bl cells (approximately 1.5104 cell/well). Infectivity 
was quantified as luciferase activity (RLU) 48 h after infec-
tion. Half-maximal inhibitory concentrations (IC50) are the 
concentrations required to inhibit infection by 50% com-
pared with the control, and were calculated using the 
dose-response-inhibition model with a variable slope in 
GraphPad Prism, version 5.0 (GraphPad Software Inc., La 
Jolla, CA, USA). 
 
1.5  Sequence and statistical analysis 
Sequences were aligned together with selected sub-
types/circulating recombinant forms of geographic im-
portance using the ClustalW program [30]. A phylogenetic 
analysis was performed with the neighbor-joining method 
with the Mega package [31]. The reliability of the branching 
orders was tested by the bootstrap analysis of 1000 replica-
tions [32]. 
2  Results 
2.1  Functional cloning of full-length gp160 envelope 
genes from patient PBMC 
Our laboratory recently characterized the neutralization 
sensitivity of HIV-1 env clones isolated from chronically 
infected patients in China [28,29]. We identified two 
CRF08-BC env clones (CNE47 and CNE48), isolated at a 
single time point from the same individual, which displayed 
substantial differences in their sensitivity to VRC01 neu-
tralization. To study the potential persistence of these vari-
ants, we collected two subsequent PBMC samples, ap-
proximately 18 and 24 months later, from this individual. 
The full-length gp160 env genes were PCR amplified and 
cloned directly into a eukaryotic expression vector. A total 
of 52 and 43 isolates were successfully cloned from sample 
20090121 and 20090720, respectively. Pseudotyped viruses 
were generated by the cotransfection of 293T cells with 
each of these expression vectors together with a pNL4-3R- 
E-luciferase viral backbone plasmid. The capacity of the 
envelope to mediate viral entry was then tested by inoculat-
ing TZM-bl cells (approximately 1.5104 cell/well) with the 
pseudotyped virus and measuring the luciferase activity 
(RLU) 48 h after infection. As shown in Figure 1, the ma-
jority of clones (45/52 from sample 20090121 and 30/43 
from sample 20090720) were functional in terms of medi-
ating viral entry, because their luciferase activity was simi-
lar to that of the positive control (CNE47). However, the 
positive clones differed in their entry efficiency, and seven 
from sample 20090121 and 13 from sample 20090720 
failed to facilitate viral entry and their average luciferase 
activities were well below 1000 RLU (Figure 1). 
2.2  Two clusters of envelope sequences were identified 
in the patient’s PBMC 
To study the genetic features of these functional clones 
(45+30=75), we first conducted a sequencing analysis. 
Among the 45 clones from sample 20090121, 24 were 
unique, whereas among the 30 clones from sample 
20090720, 12 were unique in terms of their nucleotide se-
quences. A phylogenetic analysis showed that these se-
quences fell into two major clusters: cluster 1 was closely 
related with the original CEN47 and CNE48, whereas clus-
ter 2 was quite distant (Figure 2). The intracluster genetic 
distance was 0.019±0.003 for cluster 1 and 0.005±0.001 for 
cluster 2, whereas the intercluster distance was 0.039±0.006. 
Overall, cluster 1 was genetically more closely related to 
CNE47 and CNE48 (0.034±0.005) than to cluster 2 
(0.042±0.007), suggesting that in evolutionary terms, the 
sequences in cluster 1 shared the same lineage with CNE47 
and CNE48, whereas those in cluster 2 belonged to a rela-
tively distant lineage. 
Close examination of the phylogenetic tree revealed that 
all the sequences in cluster 1 were derived from sample 
20090121, and all the sequences in cluster 2 were from 
sample 20090720. Because these two samples were col-
lected only six months apart, their distinct sequence features 
suggest that the two clusters were probably evolving inde-
pendently, although the original ancestor of both clusters is 
uncertain. It must be noted that because the full-length 
gp160 sequences were amplified directly from PBMC, 
without prior limiting dilution for single-genome amplifica-
tion, the exact proportions and their fluctuations in the 
VRC01-resistant strains relative to the sensitive strains must 
be interpreted with caution. Furthermore, the sequences in 
both clusters were genetically more closely related to the 
prototype reference sequence 08.BC.CN.GX_6F than to any 
other sequence (Figure 2), consistent with our previous 
findings. 
2.3  Analysis of amino acid variations in the 
VRC01-binding domain 
Structural analysis of VRC01 bound to monomeric gp120 
showed that it binds to the CD4bs, largely through loop D, 
the CD4-binding loop, the base of the V5 loop region, and 
β24 [33]. To study the evolutionary changes in the amino 
acid residues in these regions, the full-length gp160 nucleo-
tide sequences were translated into amino acid sequences 
and aligned with references HXB2, CNE47, and CNE48 
(Figure 3). In the hypervariable regions, including V1, V2, 
V3, V4, and V5, significant differences were found between 
the sequences from samples 20090121 and 20090720, in-
cluding both mutational variations and length polymor-
phisms. This finding supports the phylogenetic analysis, in 
which the sequences from the samples were separated 
largely because of these non-silent mutations in the hyper- 
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Figure 2  Unrooted neighbor-joining tree showing the genetic relation-
ships among the full-length gp160 envelope clones. The horizontal branch 
lengths are drawn to scale so that the relatedness of different sequences can 
be readily assessed. Sequences in two clusters are indicated. A number of 
commonly used reference sequences for classifying HIV-1 subtypes and 
circulating recombinant forms and several previously characterized vari-
ants from China (CNE series) are included. The reliability of the branching 
order was tested by a bootstrap analysis of 1000 replications and those with 
100% confidence are indicated [32]. 
variable regions. In contrast, loop D and the CD4-binding 
loop were extremely well conserved (Figure 3). This finding 
suggests that any changes in viral sensitivity to VRC01 are 
probably confined to residues within the V5 region rather  
than involving residues in the other VRC01-binding do-
mains. 
2.4  Persistence of VRC01-resistant strains throughout 
the study period 
To study the viral sensitivity to VRC01 neutralization, we 
generated two representative pseudotyped viruses from the 
full-length gp160 genes from samples 20090121 and 
20090720. These two gp160 genes (#5 and #61) were se-
lected based on their unique V5 regions, because no se-
quence variations were found in loop D or the CD4-binding 
loop compared with the original CNE47 and CNE48 (Figure 
3). As shown in Figure 4, the pseudotyped viruses built 
from the two envelopes were as resistant to VRC01 
(IC50=15.14 g mL1 for #5 and IC50=11.75 g mL1 for 
#61) as CNE47 (IC50=9.27 g mL1) (Table 2). Like the 
original CNE47 and CNE48, both clones maintained their 
natural resistance to b12. However, all the pseudotyped vi-
ruses were sensitive to neutralization by Ibalizumab (Figure 
4, Table 2). Close examination of the V5 amino acid se-
quences revealed that both clones #5 and #61 contained a 
single asparagine residue at position 460 (N460), a potential 
PNGS, which we have previously shown is critical in con-
ferring VRC01 resistance [29]. No other PNGSs were iden-
tified in the V5 region of the two clones, although two addi-
tional residues (Asn and Glu) were inserted into the V5 re-
gion of clone #61 relative to that of #5 (Figure 3, Table 2). 
Mutational changes from Gln to Lys and Thr at position 458 
were found in clones #5 and #61, respectively, and from Thr 
to Ile at position 467 in clone #61 compared with the origi-
nal CNE47 sequence. None of these changes seems to have 
had any significant effect on viral sensitivity to VRC01, 
because neither #5 nor #61 differs dramatically from 
CNE47 in terms of their VRC01 sensitivity. Nevertheless, 
these results suggest that VRC01-resistant viruses persist 
and increase in their proportion of the infecting viruses in 
the peripheral blood, despite genetic mutations arising dur-
ing antiretroviral therapy. 
3  Discussion 
In this study, we have characterized the evolutionary fea-
tures of full-length gp160 from an HIV-1-infected individual 
Table 2  Neutralization sensitivity to VRC01, b12, and ibalizumab 
Clone 
Sequence Neutralization 
V5/β24 VRC01 b12 Ibalizumab 
(458469) IC50 % of IC50 % of IC50 % of 
(μg mL1) CNE47 (μg mL1) CNE47 (μg mL1) CNE47 
CNE47 GGQTNET-NNT-E TFR 9.27 100 >50 100 0.17 100 
5 GGKTNET-NNT-E TFR 15.14 163.32 >50 100 0.09 52.94 
61 GGTTNSTNNNTEEIFR 11.75 126.75 >50 100 0.17 100 
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Figure 4  Comparison of representative envelope clones (#5 and #61) derived from mutant viruses with the original CNE47 and CNE48, in terms of their 
neutralization sensitivities to VRC01, b12, and ibalizumab. Both representative clones showed similar levels of resistance to VRC01 as CNE47. None of 
these mutations altered their sensitivity to b12 or ibalizumab neutralization. 
whom we had previously shown to harbor VRC01-resistant 
strains. A genetic analysis identified significant changes in 
the hypervariable regions of gp160 during the study period, 
including both mutational variations and length polymor-
phisms. Phenotypic characterization of representative gp160 
clones showed the persistence of the VRC01-resistant phe-
notype during the course of antiretroviral therapy. As in the 
original CNE47, the resistant phenotype was strongly asso-
ciated with N460, a potential PNGS in the V5 region. The 
persistence and continuous evolution of VRC01-resistant 
HIV-1 in vivo will pose challenges to our future preventa-
tive and therapeutic interventions based on VRC01. 
This is not the first report of VRC01-resistant strains of 
HIV-1. However, the mechanisms underlying the generation 
of these strains remain poorly understood, as do their evolu-
tionary mechanisms in vivo. Although we have shown that 
N460 in the V5 region is critical for viral sensitivity to 
VRC01 in CRF08-BC-infected patients, we cannot exclude 
the possibility that other factors also confer resistance to 
VRC01. Further research is required to determine the im-
pact of these V5 mutations on VRC01 sensitivity in a 
broader range of viral strains, especially viruses isolated 
from patients with VRC01-like neutralization activity. Fur-
thermore, because many infected individuals do not show a 
detectable VRC01-like antibody response, many VRC01- 
resistant viral variants are probably generated by random 
genetic mutations, and once they are generated, their per-
sistence or turnover will be dependent on factors other than 
VRC01-like antibody responses. It is unlikely that their per-
sistence in this individual was directly related to his an-
tiretroviral therapy because the viral loads in the plasma 
were well suppressed and there was no rebound of resistant 
viruses. Alternatively, if a VRC01-like antibody response 
did exist at some period during infection, the generation and 
turnover of VRC01-resistant strains would then be largely 
dependent on the magnitude and duration of that response. 
In either case, the sheer presence and persistence of 
VRC01-resistant HIV-1 will pose tremendous challenges to 
anti-HIV-1 strategies based on VRC01. Strategies involving 
other bnmAbs, together with VRC01, will probably be more 
efficacious than those based on VRC01 alone. 
Efforts are being made to develop novel immunogens 
and immunization strategies that can induce potent an-
ti-CD4bs antibodies [3440]. VRC01 remains one of the 
leading mAbs for HIV-1 prevention research and develop-
ment, but the natural emergence of HIV-1 resistance has 
caused uncertainty about its broader use. Nonetheless, de-
tailed analyses of VRC01 escape mechanisms and patterns 
of evolution increase our understanding of the interactions 
between the virus and the immune system in vivo, so that 
we can better target strategies to address treatment re-
sistance. More studies are required to fully understand how 
the virus circumvents neutralization, particularly analyses of 
VRC01 sensitivity in a broader range of viral strains and 
their associated biological properties. Such research will 
undoubtedly optimize the development process and maxim-
ize the potential use of VRC01 in the clinical setting. 
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